By PPN News Staff
The FDA approved sulbactam and durlobactam (SUL+DUR; Xacduro, Innoviva Specialty Therapeutics) co-packaged for IV use to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of Acinetobacter baumannii–calcoaceticus complex.
SUL+DUR is indicated for adults who are 18 years of age and older.
The FDA approval was based on data that included results from the landmark phase 3, multicenter,